Provided by Tiger Trade Technology Pte. Ltd.

Tscan Therapeutics, Inc.

1.16
+0.01000.87%
Post-market: 1.170.0100+0.86%16:10 EDT
Volume:438.79K
Turnover:513.42K
Market Cap:69.72M
PE:-1.16
High:1.20
Open:1.15
Low:1.13
Close:1.15
52wk High:2.57
52wk Low:0.8824
Shares:60.10M
Float Shares:44.03M
Volume Ratio:0.51
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0000
EPS(LYR):-1.0000
ROE:-71.28%
ROA:-27.88%
PB:0.57
PE(LYR):-1.16

Loading ...

TScan Therapeutics to present ASGCT meeting poster on CD45-targeted TCR-T therapies

Reuters
·
Apr 28

TScan Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 08

TScan Therapeutics Consolidates Finance Leadership After Officer Resignation

TIPRANKS
·
Apr 02

TScan VP Finance Dworak resigns; CFO Amello named principal accounting officer

Reuters
·
Apr 02

TScan Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 04

TScan Therapeutics Q4 net loss widens

Reuters
·
Mar 04

TScan posts Q4 net loss of USD 23.0 million (35.8%)

Reuters
·
Mar 04

TScan Therapeutics Q4 Income From Operations USD -23.858 Million

THOMSON REUTERS
·
Mar 04

TScan Therapeutics Q4 Net Income USD -22.977 Million

THOMSON REUTERS
·
Mar 04

TScan Therapeutics Inc: Cash and Cash Equivalents Continue to Fund Operations Into Second Half of 2027

THOMSON REUTERS
·
Mar 04

TScan Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Mar 02

BRIEF-Tscan Therapeutics Completes Enrollment In Cohort C Of Phase 1 Alloha™ Trial

Reuters
·
Feb 26

FDA clears TScan Therapeutics INDs for TSC-102-A01 and TSC-102-A03

Reuters
·
Feb 26

TScan Therapeutics Inc: Plans to Initiate Phase 1 Study of Both Tsc-102 Candidates in Second Half of 2026

THOMSON REUTERS
·
Feb 26

Lynx1 Capital Management Reports Acquisition of TScan Therapeutics Common Shares

Reuters
·
Dec 24, 2025

TScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies

Reuters
·
Dec 07, 2025

TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026

Reuters
·
Dec 04, 2025

TScan Therapeutics Approves Key Employee Retention Program

TIPRANKS
·
Nov 27, 2025

TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31

Reuters
·
Nov 20, 2025

TScan Therapeutics (TCRX) was downgraded to a Hold Rating at Morgan Stanley

TIPRANKS
·
Nov 14, 2025